Reacción a "EMA recommends not to approve lecanemab against Alzheimer's disease"

Based on the clinical trial evidence of only very modest efficacy, that would just not be noticeable in an individual person with Alzheimer’s disease and that cannot be considered clinically meaningful by any objective measure, and the real risks of harms from brain swelling and bleeding, EMA have made the right decision in my opinion.  

We all want to see treatments for this terrible condition. I have worked in the field for more than 30 years and am as impatient as anyone for something to offer my patients and their families. But I don’t want them to be given false hope or to be exposed to a treatment that is more likely to harm than to help. EMA have looked carefully at the trial data and their decision reflects their conclusion that lecanemab is more likely to harm people with Alzheimer’s disease than to help them. On behalf of my patients and colleagues, I would want to thank them for their work and for coming to what must have been a difficult decision to reach and to express.